Regarding the candidate targets, estrogen receptor (ESR1) showed the highest degree (113°), followed by PTGS2 (86°), NOS2 (81°), PPARG (60°), and GSK3B (56°), which demonstrated the potential therapeutic effect of each drug in LXJD formula for ameliorating psoriasis. The gene discussed is ESR1; the disease is psoriasis.